TG Therapeutics, Inc. (NASDAQ:TGTX) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of TG Therapeutics, Inc. (NASDAQ:TGTX) have been assigned an average rating of “Moderate Buy” from the six research firms that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $29.83.

Several analysts have recently weighed in on TGTX shares. The Goldman Sachs Group raised their price objective on shares of TG Therapeutics from $12.00 to $13.00 and gave the stock a “neutral” rating in a report on Thursday, February 29th. JPMorgan Chase & Co. reiterated an “overweight” rating and issued a $25.00 price objective on shares of TG Therapeutics in a research report on Thursday, April 18th. HC Wainwright increased their target price on TG Therapeutics from $45.00 to $49.00 and gave the stock a “buy” rating in a report on Thursday, May 2nd. LADENBURG THALM/SH SH upped their price target on shares of TG Therapeutics from $39.00 to $40.00 and gave the stock a “buy” rating in a research report on Thursday, May 2nd. Finally, B. Riley raised their price objective on shares of TG Therapeutics from $24.00 to $29.00 and gave the company a “buy” rating in a research report on Monday, February 5th.

TG Therapeutics Price Performance

Shares of TGTX stock opened at $17.12 on Thursday. The stock’s fifty day simple moving average is $15.37 and its 200 day simple moving average is $14.68. TG Therapeutics has a one year low of $6.46 and a one year high of $35.22. The firm has a market cap of $2.65 billion, a price-to-earnings ratio of 74.43 and a beta of 2.33. The company has a debt-to-equity ratio of 0.62, a current ratio of 5.92 and a quick ratio of 5.18.

TG Therapeutics (NASDAQ:TGTX) last issued its earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.02). The firm had revenue of $63.47 million during the quarter, compared to analyst estimates of $54.60 million. TG Therapeutics had a net margin of 14.24% and a return on equity of 33.79%. The firm’s revenue for the quarter was up 713.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.28) EPS. On average, analysts expect that TG Therapeutics will post -0.11 earnings per share for the current fiscal year.

Insider Buying and Selling at TG Therapeutics

In other TG Therapeutics news, Director Laurence N. Charney sold 22,000 shares of the firm’s stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $15.97, for a total value of $351,340.00. Following the transaction, the director now directly owns 215,229 shares of the company’s stock, valued at $3,437,207.13. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 9.20% of the company’s stock.

Institutional Investors Weigh In On TG Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in TGTX. 683 Capital Management LLC acquired a new stake in TG Therapeutics in the third quarter worth $11,286,000. Norges Bank bought a new position in TG Therapeutics during the fourth quarter worth about $18,362,000. Schonfeld Strategic Advisors LLC lifted its holdings in TG Therapeutics by 164.5% during the third quarter. Schonfeld Strategic Advisors LLC now owns 1,367,400 shares of the biopharmaceutical company’s stock worth $11,431,000 after acquiring an additional 850,507 shares in the last quarter. Rafferty Asset Management LLC grew its stake in TG Therapeutics by 183.2% in the third quarter. Rafferty Asset Management LLC now owns 856,837 shares of the biopharmaceutical company’s stock valued at $7,163,000 after acquiring an additional 554,309 shares during the period. Finally, Eventide Asset Management LLC bought a new stake in shares of TG Therapeutics in the fourth quarter worth about $7,506,000. Institutional investors own 58.58% of the company’s stock.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.